Service
Information for
About JCCM
Links
Effect of short term sibutramine on gonadotropin spontaneous pulsatile release in normogonadotropinemic amenorrheic subjects
- Alessandro D Genazzani，Chiara Lanzoni，Federica Ricchieri，Annalisa Campedelli，Erika Rattighieri，Susanna Santagni，Valerio M Jasonni Department of Obstetrics and Gynecology,University of Modena and Reggio Emilia,Modena 41100,Italy Correspondence to Alessandro Genazzani,MD,Department of Obstetrics and Gynecology,University of Modena and Reggio Emilia,Modena,Via del Pozzo 71 Modena 41100,Italy E-mail: algen@unimo.it
[Abstract]Objective To evaluate the effect of sibutramine on luteinizing hormone（LH） secretion. Methods Setting :amenorrheic patients in a clinical research environment. Patients :10 healthy normogonadotropic amenorrheic volunteers were enrolled after informed consent. Interventions :All patients underwent hormonal evaluations, an oral glucose tolerance test （OGTT）, a naloxone test, a pulsatility study and a gonadotropin-releasing hormone（GnRH） stimulation test before and after 7 d of sibutramine administration （10 mg/d）. Main outcome measures: plasma LH,follicle stimulating hormone, prolactin（PRL）, estradiol, 17-hydroxy-progesterone, androstenedione, testosterone, glucose,insulin, C-peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio. Pulsatility study and instantaneous secretory rates（ISR） were computed using the DETECT algorithm. Results After sibutramine administration, plasma LH increased, PRL decreased, insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved. While LH pulse frequency and LH response to GnRH bolus did not change under sibutramine adminstration, LH pulse amplitude increased as well as LH response to naloxone infusion. Conclusion Sibutramine admnistration allows to suggest that the negative modulation of the opioidergic pathway on GnRH secretion is under the influence of the serotonergic system.
[Document Indexing]
Alessandro D Genazzani，Chiara Lanzoni，Federica Ricchieri，Annalisa Campedelli，Erika Rattighieri，Susanna Santagni，Valerio M Jasonni.Effect of short term sibutramine on gonadotropin spontaneous pulsatile release in normogonadotropinemic amenorrheic subjects.Journal of Chinese Clinical Medicine,2008,3(7):361-369.
[Reference Document]
1. Genazzani AD,Gastaldi M,Petraglia F,Gamba O,Florio P,Corazza F,et al.Neuroendocrinology of the menstrual cycle.In:Internaz.Gynecologic Endoscopic Surgery.Roma,Italy:CIC,1994:48-54
2. Genazzani AD.Neuroendocrine aspects of amenorhea related to stress.Ped End Rev,2005,2:661-668.
3. Caretti N,Florio P,Bertolin A,Costa CVL,Allegri G,Zilli G.Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization.Hum reprod,2005,6:1548-1553.
4. Berendsen HH.The role of serotonin in hot flushes.Maturitas,2000,36:155-164.
5. Godoy-Matos A,Carraro L,Vieira A,Oliveira J,Guedes OP,Mattos L,et al.Treatment of obese adolescents with sibutramine:a randomized,double-blind,controlled study.J Clin Endocrinol Metab,2005,90:1460-1465.
6. Sabuncu T,Harma M,Harma M,Nazligul Y,Kilic F.Sibutramine has a postive effect on clinical and metabolic parameters in obese patients with polycyctic ovary syndrome.Fertil Steril,2003,80:1199-1204.
7. Genazzani AD,Petraglia F,Benatti R,Montanini V,Algeri I,Volpe A,et al.Luteinizing hormone （LH） secretory burst duration is indipendent from LH,prolactin or gonadal steroid plasma levels in amenorrheic women.J Clin Endocrinol Metab,1991,72:1220-1225.
8. Kolodziejczyk B,Duleba AJ,Spaczynski RZ,Pawelczyk L.Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.Fertil Steril,2000,73:1149-1154.
9. Legro RS,Finegood D,Dunaif A.Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.J Clin Endocrinol MetabM,1998,83:2694-2698.
10. Genazzani AD,Petraglia F,Gastaldi M,Volpogni C,Gamba O,Genazzani AR.Naltrexone treatment restores menstrual cycles in patients with weight loss-realted amenorrhea.Fertil Steril,1995,64:951-956.
11. Genazzani AD,Petraglia F,Fabbri G,Monzani A,Montanini V,Genazzani AR.Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss.Fertil Steril,1990,54:222-226.
12. Genazzani AD,Petraglia F,Pianazzi F,Volpogni C,Genazzani AR.The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatilee releases distinguishes adrenal from ovarian hyperandrogenism.Gynecol Endocrinol,1993,7:33-41.
13. Oerter KE,Guardabasso V,Rodabrd D.Detection and characterization of peaks and estimation of instantaneous secretory rate for episodic pulsatile hormone secretion.Computers and Biomedical Research,1986,19:170-191.
14. Genazzani AD.Application of peak-detection programs to clinical data.In:Guardabasso V,Rodbard D,Forti G.Computers in Endocrinology:Recent Advances.New York:Raven Press,1990:71-82.
15. Genazzani AD,Rodbard D.Evaluation of methods for detection of pulsatile hormone secretion:sensitivity vs.specificity.Acta Endocrinol （Copenhagen）,1991,124:295-306.
16. Genazzani AD,Rodbard D,Forti G,Petraglia F,Baraghini GF,Genazzani AR.Estimation of instantaneous secretory rate of luteinizing hormone in woman during the menstrual cycle and in man.Clin Endocrinol,1990,32:573-581.
17. Veldhuis JD,Fraioli F,Rogol AD,Dufau ML.Metabolic clearance of biologically active luteinizing hormone in man.J Clin Invest,1986,77:1122-1127.
18. Negro-Vilar A,Ojeda SR,McCann SM.Catecholaminergic modulation of luteinizing hormone-releasing hormone release by median eminence fragments in vitro.Endocrinology,1979,104:1749-1757.
19. Ledaem CA,Crowley WR,Simpkins JW & Lara SP.Effects of naloxone on catecholamine and LHRH release from the perifused hypothalamus of steroid-primed rats.Neuroendocrinology,1985,40:497-500.
20. Masotto C & Negro-Vilar A.Activation of gamma-aminobutyric acid B-receptors abolishes naloxone-stimulate luteinizing hormone release.Endocrinology,1987,121:2251-2255.
21. Moretto M,Lo′pez FJ & Negro-Vilar A.Nitric oxide regulates luteinizing hormone-releasing hormone secretion.Endocrinology,1993,133:2399-2402.
22. Lopez FJ & Negro-Vilar A.Galanin stimulates luteinizing hormone-releasing hormone secretion from arcuate nucleus-median eminence fragments in vitro:involvement of an a-adrenergic mechanism.Endocrinology,1990,127:2431-2436.
23. Brann DW & Mahesh VB.Excitatory amino acids:evidence for a role in the control of reproduction and anterior pituitary secretion.Endocrine Reviews,1997,18:678-700.
24. Vitale ML & Chiocchio SR.Serotonin,a neurotransmitter involved in the regulation of luteinizing hormone release.Endocrine Reviews,1993,14:480-493.
25. Genazzani AR,Genazzani AD,Volpgni C,Pianazzi F,Guo AL,Surico N,et al.Opioid control of gonadotropin secretion in humans.Hum reprod,1993,8:151-153.
26. Moguilevski JA,Faigon MR,Rubio MC,Scacchi P & Szwarcfarb B.Sexual differences in the effect of serotonin on LH secretion in rats.Acta Endocrinologica,1985,109:320-325.
27. Justo SN,Rossano GL,Szwarcfarb B,Rubio MC & Moguilevski JA.Effect of serotoninergic system on FSH secretion in male and female rats:evidence for stimulatory and inhibitory actions.Neuroendocrinology,1989,50:382-386.
28. Pinilla L,Gonzalez LC,Tena-Sempere M,Aguilar E.5-HT1 and 5-HT2 receptor activation reduces N-methyl-D-aspartate （NMDA）-stimulated LH secretion in prepubertal male and female rats.Eur J Endocrinol,2003,148:121-127.
29. Hoyer D & Schoeffer P.5-HT receptors:subtypes and second messengers.Journal of Receptor Research,1991,11:197-214.
30. Hartig PR,Branchek TA & Weinshank RL.A subfamily of 5-HT1D receptor genes.Trends in Pharmacological Sciences,1992,13:152-159.
31. Receptor and Ion Channel Nomenclature Supplement （RNS）.Trends in Pharmacological Sciences,1997,（Suppl）:1-84.
32. Coletta DK,Bates SH,Jones RB,Bailey CJ.The sibutramine metabolite M2 improves muscle glucose update and reduces hepatic glucose output:preliminary data.Diabetes Vasc Dis Res,2006,3:186-188.
33. Jorge SD,Pobbe RLH,de Paula Soares V,De Oliveira AM,Zangrossi H jr.Effects of sibutramine on anxiety-related behaviours in rats.Pharmacol Res,2004,50:517-522.
34. Balcioglu A,Wurtman RJ.Sibutramine,a serotonin uptake inhibitor,increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid.Neuropharmacology,2000,39:2352-2359.
35. Berkovitz RI,Wadden TA,Tershakovec AM,Cronquist JL.Behaviour threapy and sibutramine for the treatment of adolescent obesity.JAMA,2003,289:1805-1812.
36. Godoy-Matos A,Carraro L,Viera A,Oliveira J,Guedes EP,Mattos L,et al.Treatment of obese adolescents with sibutramine:a randomized,double-blind,controlled study.J Clin Endocrinol Metab,2005,90:1460-1465.
37. Lindholm A,Bixo M,Bjorn I,Wolner-Hanssen P,Eliasson M,Larsson A,et al.Effect of sibutramine on weight reduction in women with polycystic ovary syndrome:a randomized,double-blind,placebo-controlled trial.Fertil Steril,2007,in press.
38. Beijerink NJ,Kooistra HS,Dieleman SJ,Okkens AC.Serotonin antagonist-induced lowering of prolactin secretion does not affect the pattern of pulsatile secretion of follicle-stimulating hormone and luteinizing hormone in the bitch.Reproduction,2004,128:181-188.
39. Genazzani AD,Gastaldi M,Volpe A,Petraglia F,Genazzani AR.Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea.Gynecol Endocrinol,1995,9:325-334.
40. Smith MJ,Jennes L.Neural signals that regulate GnRH neurones directly during the oestrous cycle.Reproduction,2001,122:1-10.
41. Petraglia F,Porro C,Facchinetti F,Cicoli C,Bertellini E,Volpe A,et al.Opioid control of LH secretion in humans:menstrual cycle,menopause and aging reduced effect of naloxone but not of morphine.Life Sci,1986,38:2103-2110.
42. Genazzani AD,Rodbard D,Forti G,Petraglia F,Baraghini GF,Genazzani AR.Estimation of instantaneous secretory rate of luteinizing hormone in woman during the menstrual cycle and in man.Clin Endocrinol,1990,32:573-581.
43. Bailey CJ,Turner SL,Bates SH,Jones RB.Sibutramine metabolites increase glucose transport by cultured muscle cells.In J Obes,2001,25:478-485.
